Maximizing the effect of an α7 nicotinic receptor PAM in a mouse model of schizophrenia-like sensory inhibition deficits

Brain Research

Volumn 1611, Issue , 2015, Pages 8-17

  Stevens, Karen E ^a   Zheng, Lijun ^a   Floyd, Kirsten L ^a   Stitzel, Jerry A ^b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Auditory gating; C3H heterozygote Chrna7 null mutant mice; DBA 2 mice; PAM; PNU 120596; Positive allosteric modulator; Schizophrenia; Sensory inhibition; 7 Nicotinic receptor

Indexed keywords

1 (5 CHLORO 2,4 DIMETHOXYPHENYL) 3 (5 METHYL 3 ISOXAZOLYL)UREA; BUNGAROTOXIN RECEPTOR; CHOLINE; 1-(5-CHLORO-2,4-DIMETHOXYPHENYL)-3-(5-METHYLISOXAZOL-3-YL)UREA; CARBANILAMIDE DERIVATIVE; CHRNA7 PROTEIN, MOUSE; ISOXAZOLE DERIVATIVE;

ANIMAL MODEL; ARTICLE; BRAIN LEVEL; C3H MOUSE; DBA 2 MOUSE; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; HETEROZYGOTE; HIPPOCAMPUS; LOW DRUG DOSE; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; SCHIZOPHRENIA; SENSORY DYSFUNCTION; SENSORY INHIBITION DEFICIT; AGONISTS; ANIMAL; AUDITORY STIMULATION; DBA MOUSE; DISEASE MODEL; DRUG EFFECTS; FEMALE; GENETICS; HEARING; MALE; PATHOPHYSIOLOGY; PHYSIOLOGY; SENSORY GATING; TRANSGENIC MOUSE;

MUS;

ACOUSTIC STIMULATION; ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR; ANIMALS; AUDITORY PERCEPTION; CHOLINE; DISEASE MODELS, ANIMAL; FEMALE; HETEROZYGOTE; HIPPOCAMPUS; ISOXAZOLES; MALE; MICE; MICE, INBRED C3H; MICE, INBRED DBA; MICE, TRANSGENIC; PHENYLUREA COMPOUNDS; SCHIZOPHRENIA; SENSORY GATING;

EID: 84929605847     PISSN: 00068993     EISSN: 18726240     Source Type: Journal    
DOI: 10.1016/j.brainres.2015.02.044     Document Type: Article

References (67)

1. C.E. Adams, J.C. Yonchek, K.M. Schulz, S.L. Graw, J. Stitzel, P.U. Teschke, and K.E. Stevens Reduced Chrna7 expression in mice is associated with decreases in hippocampal markers of inhibitory function: implications for neuropsychiatric diseases Neuroscience 207 2012 274 282
2. C.E. Adams, J.C. Yonchek, L. Zheng, A.C. Collins, and K.E. Stevens Altered hippocampal circuit function in C3H alpha7 null mutant heterozygous mice Brain Res. 1194 2008 138 145
3. L.E. Adler, R. Freedman, R.G. Ross, A. Olincy, and M.C. Waldo Elementary phenotypes in the neurobiological and genetic study of schizophrenia Biol. Psychiatry 46 1999 8 18
4. L.E. Adler, L.J. Hoffer, J. Griffith, M. Waldo, and R. Freedman Normalization by nicotine of deficient auditory sensory gating in the relatives of schizophrenics Biol. Psychiatry 32 1992 607 616
5. L.E. Adler, L.J. Hoffer., A. Wiser, and R. Freedman Transient normalization of a defect in auditory sensory processing in schizophrenics following cigarette smoking Am. J. Psychiatry 150 1993 1856 1861
6. L.E. Adler, A. Olincy, M. Waldo, J.G. Harri, J. Griffith, K. Stevens, K. Flach, H. Nagamoto, P. Bickford, S. Leonard, and R. Freedman Schizophrenia, sensory gating, and nicotinic receptors Schizophr. Bull. 24 1998 189 202
7. E.X. Albuquerque, E.F. Pereira, M.F. Braga, and M. Alkondon Contribution of nicotinic receptors to the function of synapses in the central nervous system: the action of choline as a selective agonist of alpha7 receptors J. Physiol. 92 1998 309 316
8. M. Alkondon, E.F. Pereira, H.M. Eisenberg, and E.X. Albuquerque Choline and selective antagonists identify two subtypes of nicotinic acetylcholine receptors that modulate GABA release from CA1 interneurons in rat hippocampal slices J. Neurosci. 19 1999 2693 2705
9. C. Bray, J.H. Son, P. Kumar, and S. Meizel Mice deficient in CHRNA7, a subunit of the nicotinic acetylcholine receptor, produce sperm with impaired motility Biol. Reprod. 73 2005 807 814
10. C.M. Cullum, J.G. Harris, M.C. Waldo, E. Smernoff, A. Madison, H.T. Nagamoto, J. Griffith, L.E. Adler, and R. Freedman Neurophysiological and neuropsychological evidence for attentional dysfunction in schizophrenia Schizophr. Res. 10 1993 131 141
11. T. Dinklo, H. Shaban, J.W. Thuring, H. Lavreysen, K.E. Stevens, L. Zheng, C. Mackie, C. Grantham, I. Vandenberk, G. Meulders, L. Peeters, H. Verachtert, E. De Prins, and A.S. Lesage Characterization of 2-[[4-fluoro-3-(trifluoromethyl)phenyl]amino]-4-(4-pyridinyl)-5-thiazolemethanol (JNJ-1930942), a novel positive allosteric modulator of the {alpha}7 nicotinic acetylcholine receptor J. Pharmacol. Exp. Ther. 336 2011 560 574
12. T. Di Paolo, L. Gregoire, D. Feuerbach, W. Elbast, M. Weiss, and T. gomez-Mancilla AQW051, a novel and selective nicotinic acetylcholine receptor α7 partial agonist, reduces L-Dopa-induced dyskinesias and extends the duration of L-Dopa effects in parkinsonian monkeys Parkinsonism Relat. Disord 20 2011 1119 1123
13. R. Faghih., G.A. Gfesser, and M. Gopalakrishnan Advances in the discovery of novel positive allosteric modulators of the alpha7 nicotinicacetylcholine receptor Recent Pat. CNS Drug Discov. 2 2007 99 106
14. D. Fayuk, and J.L. Yakel Regulation of nicotinic acetylcholine receptor channel function by acetylcholinesterase inhibitors in rat hippocampal CA1 interneurons Mol. Pharmacol. 66 2004 658 666
15. R. Freedman α7-nicotinic acetylcholine receptor agonists for cognitive enhancement in schizophrenia Annu. Rev. Med. 65 2014 245 261
16. R. Freedman, C.E. Adams, L.E. Adler, P.C. Bickford, J. Gault, J.G. Harris, H.T. Nagamoto, A. Olincy, R.G. Ross, K.E. Stevens, M. Waldo, and S. Leonard Inhibitory neurophysiological deficit as a phenotype for genetic investigation of schizophrenia Am. J. Med. Genet. 97 2000 58 64
17. R. Freedman, C.E. Adams, and S. Leonard The alpha7-nicotinic acetylcholine receptor and the pathology of hippocampal interneurons in schizophrenia J. Chem. Neuroanat. 20 2000 299 306
18. R. Freedman, L.E. Adler, M.C. Waldo, E. Pachtman, and R.D. Franks Neurophysiological evidence for a defect in inhibitory pathways in schizophrenia: comparison of medicated and drug-free patients Biol. Psychiatry 18 1983 537 551
19. R. Freedman, M. Hall, L.E. Adler, and S. Leonard Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia Biol. Psychiatry 38 1995 22 33
20. R. Freedman, A. Olincy, R.W. Buchanan, L.G. Harris, J.M. Gold, L. Johnson, D. Allensworth, A. Guzman-Bonilla, B. Clement, M.P. Ball., J. Kutnick, V. Pender, L.F. Martin, K.E. Stevens, B.D. Wagner, G.O. Zerbe, F. Sote, and W.R. Kem Initial phase 2 trial of a nicotinic agonist in schizophrenia 165 2008 1040 1047
21. M.F. Green, R.S. Kern, and R.K. Heaton Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS Schizophr. Res. 72 2004 41 51
22. M. Hajós, and B.N. Rogers Targeting alpha7 nicotinic acetylcholine receptors in the treatment of schizophrenia Curr. Pharm. Des. 16 2010 538 554
23. J.G. Harris, S. Kongs, D. Allensworth, L. Martin, J. Tregellas, B. Sullivan, G. Zerbe, and R. Freedman Effects of nicotine on cognitive deficits in schizophrenia Neuropsychopharmacology 29 2004 1378 1385
24. K. Hashimoto, M. Iyo, R. Freedman, and K.E. Stevens Tropisetron improves deficient inhibitory auditory processing in DBA/2 mice: role of alpha 7 nicotinic acetylcholine receptors Psychopharmacology 183 2005 13 19
25. R.,S. Hurst, M. Hajós, M. Raggenbass, T.M. Wall, N.R. Higdon, J.A. Lawson, K.L. Rutherford-Root, M.B. Berkenpas, W.E. Hoffmann, D.W. Piotrowski, V.E. Groppi, G. Allaman, R. Ogier, S. Bertrand, D. Bertrand, and S.P. Arneric A novel positive allosteric modulator of the alpha7 neuronal nicotinic acetylcholine receptor: in vitro and in vivo characterization J. Neurosci. 25 2005 4396 4405
26. C.K. Jones, N. Byun, and M. Bubser. Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia Neuropsychopharmacology 37 2012 16 42
27. J.A. Leiberman, G. Dunbar, A.C. Segreti, R.R. Grigis, F. Seoane, J.D. Beaver, N. Duan, and D.A. Hosford A randomized exploratory trial of an α-7 receptor agonist (TC-5619) for cognitive enhancement in schizophrenia Neruopsychopharmacology 38 2013 968 975
28. S.C. Leiser, M.R. Bowlby, T.A. Comery, and J. Dunlop A cog in cognition: how the alpha 7 nicotinic acetylcholine receptor is geared towards improving cognitive deficits Pharmacol. Ther. 122 2009 302 311
29. S. Leonard, L.E. Adler, K. Benhammou, R. Berger, C.R. Breese, C. Drebing, J. Gault, M.J. Lee, J. Logel, A. Olincy, R.G. Ross, K. Stevens, B. Sullivan, R. Vianzon, D.E. Virnich, M. Waldo, K. Walton, and R. Freedman Smoking and mental illness Pharmacol. Biochem. Behav. 70 2001 561 570
30. S. Leonard, and D. Bertrand Neuronal nicotinic receptors: from structure to function Nicotine Tob. Res. 3 2001 203 223
31. S. Leonard, C. Breese, C. Adams, K. Benhammou, J. Gault, K. Stevens, M. Lee, L. Adler, A. Olincy, R. Ross, and R. Freedman Smoking and schizophrenia: abnormal nicotinic receptor expression Eur. J. Pharmacol. 393 2000 237 242
32. L.F. Martin, and R. Freedman Schizophrenia and the alpha7 nicotinic acetylcholine receptor Int. Rev. Neurobiol. 8 2007 225 246
33. P.L. McGeer, and E.G. McGeer Possible changes in striatal and limbic cholinergic systems in schizophrenia Arch. Gen. Psychiatry 34 1977 1319 1323
34. K.L. Metzger, C.R. Maxwell, Y. Liang, and S.J. Seigel Effects of nicotine vary across two auditory evoked potentials in the mouse Biol. Psychiatry 61 2007 23 30
35. C.L. Miller, and R. Freedman The activity of hippocampal interneurons and pyramidal cells during the response of the hippocampus to repeated auditory stimuli Neuroscience 69 1995 371 381
36. S. Miyamoto, L.F. Jarskog, and W.W. Fleischhacker Alternative pharmacologic targets for the treatment of schizophrenia: results from phase I and II trials Curr. Opin. Psychiatry 2 2013 158 165
37. H.T. Nagamoto, L.E. Adler, R.A. Hea, J.M. Griffith, K.A. McRae, and R. Freedman Gating of auditory P50 in schizophrenics: unique effects of clozapine Biol. Psychiatry 40 1996 181 188
38. H.T. Nagamoto, L.E. Adler, K.A. McRae, P. Huettl, E. Cawthra, G. Gerhardt, R. Hea, and J. Griffith Auditory P50 in schizophrenics on clozapine: improved gating parallels clinical improvement and changes in plasma 3-methoxy-4-hydroxyphenylglycol Neuropsychobiology 39 1999 10 17
39. H.J. Ng, E.R. Whittemore, M.B. Tran, D.J. Hogenkamp, R.S. Broide, T.B. Johnstone, L. Zheng, K.E. Stevens, and K.W. Gee Nootropic alpha7 nicotinic receptor allosteric modulator derived from GABAA receptor modulators Proc. Natl. Acad. Sci. USA 104 2007 8059 8064
40. A. Olincy, and R. Freedman Nicotinic mechanisms in the treatment of psychotic disorders: a focus on the α7 nicotinic receptor Handb. Exp. Pharmacol. 213 2012 211 232
41. A. Olincy, J.G. Harris, L.L. Johnson, V. Pender, S. Kongs, D. Allensworth, J. Ellis, G.O. Zerbe, S. Leonard, K.E. Stevens, J.O. Stevens, L.E. Adler, F. Soti, W.R. Kem, and R. Freedman Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia Arch. Gen. Psychiatry 63 2006 630 638
42. A. Olincy, and K.E. Stevens Treating schizophrenia symptoms with an alpha7 nicotinic agonist, from mice to men Biochem. Pharmacol. 74 2007 1192 1201
43. R.L. Papke, W.R. Kem, F. Soti, G.Y. López-Hernández, and N.A. Horenstein Activation and desensitization of nicotinic alpha7-type acetylcholine receptors by benzylidene anabaseines and nicotine J. Pharmacol. Exp. Ther. 329 2009 791 807
44. G. Paxinos, and K.B.J. Franklin The Mouse Brain in Stereotaxic Coordinates 2004 Academic Press San Diego
45. D. Potter, A. Summerfelt, J. Gold, and R.W. Buchanan Review of clinical correlates of P50 sensory gating abnormalities in patients with schizophrenia Schizophr. Bull. 32 2006 692 700
46. R.J. Radek, H.M. Miner, N.A. Bratcher, M.W. Decker, M. Gopalakrishnan, and R.S. Bitner Alpha4beta2 nicotinic receptor stimulation contributes to the effects of nicotine in the DBA/2 mouse model of sensory gating Psychopharmacology 187 2006 47 55
47. R.J. Radek, H.M. Robb, K.E. Stevens, M. Gopalakrishnan, and R.S. Bitner Effects of the novel α7 nicotinic acetylcholine receptor agonist ABT-107 on sensory gating in DBA/2 mice: pharmacodynamic characterization J. Pharmacol. Exp. Ther. 343 2012 736 745
48. E.M. Sánchez-Morla, J.L. Santos, A. Aparicio, M.Á. García-Jiménez, C. Soria, and C. Arango Neuropsychological correlates of P50 sensory gating in patients with schizophrenia Schizophr Res. 143 2013 102 106
49. A.K. Szabo, k. Pesti, A. Mike, and E.S. Vizi Node of action of the positive modulator PNU-120596 on α7 nicotinic acetylcholine receptors Neuropharmacology 81 2014 42 54
50. S.J. Siegel, C.R. Maxwell, S. Majumdar, D.F. Frief, C. Lerman, R.E. Gur, S.J. Kanes, and Y. Liang Monoamine reuptake inhibition and nicotine receptor antagonism reduce amplitude and gating of auditory evoked potentials Neuroscience 133 2005 729 738
51. S. Shirazi-Southall, D.E. Rodriguez, and G.G. Nomikos Effects of typical and atypical antipsychotics and receptor selective compounds on acetylcholine efflux in the hippocampus of the rat Neuropsychopharmacology 26 2002 583 594
52. J.K. Simosky, K.E. Stevens, and R. Freedman Nicotinic agonists and psychosis Curr. Drug Targets CNS Neurol. Disord. 1 2002 149 162
53. J.K. Simosky, K.E. Stevens, W.R. Kem, and R. Freedman Intragastric DMXB-A, an alpha7 nicotinic agonist, improves deficient sensory inhibition in DBA/2mice Biol. Psychiatry 50 2001 493 500
54. A.K. Smith, J.C. Edgar, M. Huang, B.Y. Lu, R.J. Thoma, F.M. Hanlon, G. McHaffie, A.P. Jones, R.D. Paz, G.A. Miller, and J.M. Cañive Cognitive abilities and 50- and 100-msec paired-click processes in schizophrenia Am. J. Psychiatry. 167 2010 1264 1275
55. J. Smucny, A. Olincy, L.C. Eichman, E. Lyons, and J.R. Tregellas Early sensory processing deficits predict sensitivity to distraction in schizophrenia Schizophr. Res. 147 2013 196 200
56. K.E. Stevens, A.E. Bullock, and A.C. Collins Chronic corticosterone treatment alters sensory gating in C3H mice Pharmacol. Biochem. Behav. 69 2001 359 366
57. K.E. Stevens, R. Freedman, A.C. Collins, M. Hall, S. Leonard, M.J. Marks, and G.M. Rose Genetic correlation of hippocampal auditory evoked response and α-bungarotoxin binding in inbred mouse strains Neuropsychopharmacology 15 1996 152 162
58. K.E. Stevens, W.R. Kem, V. Mahnir, and R. Freedman Selective α7 nicotinic agonists normalize inhibition of auditory response in DBA mice Psychopharmacology 136 1998 320 332
59. K.E. Stevens, and K.D. Wear Normalizing effects of nicotine and a novel nicotinic agonist on hippocampal auditory gating in two animals models Pharmacol. Biochem. Behav. 57 1997 869 874
60. Y. Tani, K. Saito, M. Imoto, and T. Ohno Pharmacological characterization of nicotinic receptor-mediated acetylcholine release in rat brain - an in vivo microdialysis study Eur. J. Pharmacol. 351 1998 181 188
61. V.V. Uteshev The therapeutic promise of positive allosteric modulation of nicotinic receptors Eur. J. Pharmacol. 727 2014 181 185
62. T.L. Wallace, and D. Bertrand Neuronal nicotinic receptors as a drug target in schizophrenia Expert Opin. Ther. Targets 7 2013 139 155
63. K.M. Wildeboer, and K.E. Stevens Stimulation of the alpha4beta2 nicotinic receptor by 5-I A-85380 improves auditory gating in DBA/2 mice Brain Res. 1224 2008 29-36
64. K.M. Wildeboer-Andrud, and K.E. Stevens The smoking cessation drug varenicline improves deficient P20-N40 inhibition in DBA/2 mice Pharmacol. Biochem. Behav. 100 2011 17 24
65. D.K. Williams, J. Wang, and R.L. Papke Positive allosteric modulators as an approach to nicotinic acetylcholine receptor-targeted therapeutics: advantages and limitations Biochem. Pharmacol. 82 2011 915 930
66. G. Winterer, J. Gallinat, J. Brinkmeyer, F. Musso, J. Kornhuber, N. Thuerauf, D. Rujescu, R. Favis, Y. Sun, M.A. Franc, S. Ouwerkerk-Mahadevan, L. Janssens, M. Timmers, and J.R. Streffer Allosteric alpha-7 nicotinic receptor modulation and P50 sensory gating in schizophrenia: a proof-of-mechanism study Neuropharmacology 64 2013 197 204
67. C.M. Yee, K.H. Neuchterlien, S.E. Morris, and P.M. White P50 suppression in recent-onset schizophrenia: Clinical correlates and resperidone effects J. Abnorm. Psychol. 107 1998 691 698